<div id="readability-page-1"><div>(TheNewswire)<ul><ul></ul></ul>Winnipeg – March 6, 2026 –TheNewswire — Cytophage Technologies Ltd. (“Cytophage” or the“Company”) (TSXV: CYTO; FSE: 70G) today announced that its Boardof Directors (the “Board”) has formed a special committeecomprised solely of independent and disinterested directors (the“Special Committee”) to evaluate potential strategicalternatives.The Company is currently in receipt of unsolicitedstrategic financing proposals. The Special Committee will oversee acompetitive process to assist all interested parties in conducting duediligence and reaching, if possible, a firm and final financing offer. The Special Committee is further exploring a full range of options,which may include, but are not limited to, a merger, sale, or otherbusiness combination. The Special Committee is focused on acting inthe best interests of all Cytophage stockholders and maximizingvalue.The Board has not set a timetable for this process, norhas it made any decisions regarding any potential strategictransaction. There can be no assurance that this process will resultin any transaction. The Company does not intend to provide updates ormake further comments regarding these matters unless and until itdetermines that additional disclosure is appropriate or required bylaw..About Cytophage Cytophage Technologies (TSXV:CYTO / FSE: 70G) is apioneering biotechnology company dedicated to bacteriophage research,product development and commercialization. Bacteriophages are viruses that only infect and killbacteria. These natural killers of bacteria can overcome cellular ororganism-level defences. They are nature’s version ofantibiotics. Cytophage is improving bacteria’s natural predatorswith environmental as well as genetic modifications to bring safe andtoxin-free killer solutions to large addressable markets with aninitial focus on animal health. As a leading bacteriophagemanufacturer in Canada and powered by a large library of phagestrains, Cytophage is committed to addressing the global challenge ofantibiotic resistance (“AMR”). The WHO predicts that AMR will bethe leading cause of human mortality by 2050. Many countries havealready banned or limited preventative antibiotic use in animalproduction including 27 EU countries, US, Canada, Brazil, Bangladesh,India and Mexico. In addition to that, consumers all over the worldare demanding organic and antibiotic-free products. Cytophage is using its know-how and technology toadvance innovative and cost competitive products that harness thepower of bacteriophages to combat bacterial infections affecting humanhealth, animal health, and food security. For more information on Cytophage Technologies and itsinnovative work in bacteriophage therapy, please visit www.cytophage.com.For further information please contact: Cytophage Technologies Ltd.James Kinley, Chief Financial Officer: james@cytophage.comInvestor Relations: info@cytophage.comCytophage Investor Alerts: https://cytophage.com/subscribe/Cautionary Statement on Forward-LookingInformation This news release contains“forward-looking information” and “forward-looking statements”(collectively, “forward-looking statements”) within the meaning ofthe applicable Canadian securities legislation. All statements, otherthan statements of historical fact, are forward-looking statements andare based on expectations, estimates and projections as at the date ofthis news release. Any statement that involves discussions withrespect to predictions, expectations, beliefs, plans, projections,objectives, assumptions, future events or performance (often but notalways using phrases such as “expects”, or “does not expect”,“is expected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are described under the caption “RiskFactors” in Cytophage’s Filing Statement dated January 30, 2024,which is available for view on SEDAR+ at www.sedarplus.ca. These risksinclude but are not limited to, the risks associated with thebacteriophage industry, such as operational risks in development orcapital expenditures, the uncertainty of extensive regulatory approvalrequirements, government regulations, protection of intellectualproperty, product liability and rapid technological advancements.Forward-looking statements contained herein are made as of the date ofthis press release, and Cytophage disclaims, other than as required bylaw, any obligation to update any forward-looking statements whetheras a result of new information, results, future events, circumstances,or if management’s estimates or opinions should change, orotherwise. There can be no assurance that forward-looking statementswill prove to be accurate, as actual results and future events coulddiffer materially from those anticipated in such statements.Accordingly, the reader is cautioned not to place undue reliance onforward-looking statements. Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease. Copyright (c) 2026 TheNewswire - All rights reserved.</div></div>

IBBQ

Cytophage Technologies Ltd. has formed a special committee of independent directors to evaluate strategic alternatives, including unsolicited financing proposals. The committee will oversee a competitive process for interested parties to conduct due diligence and potentially reach a financing agreement. Options may include a merger, sale, or other business combinations. The Board has not set a timetable for this process and will not provide updates unless necessary. Cytophage focuses on bacteriophage research to combat antibiotic resistance in animal health and food security.

The newswire.ca

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares UltraShort Nasdaq Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Penghua SSE STAR Biology and Medicine ETF

Cytophage Announces Formation of Special Committee of Independent Directors to Evaluate Strategic Alternatives